Insomnia News and Research

Latest Insomnia News and Research

Targeting symptoms, rather than disorders, might help reduce work impact of mental health issues

Symptoms such as insomnia and emotional distress account for much of the work impact of mental health problems such as depression and anxiety, reports a study in the February issue of Medical Care.

23 Jan 2014

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.

21 Jan 2014

Technology increases cognitive behavioral therapy options for insomnia

Web- and telehealth-based delivery of cognitive behavioral therapy is effective for treating chronic insomnia, giving rural-dwelling adults more choice and better access to services, researchers report.

20 Jan 2014

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)).

18 Jan 2014

Persistent insomnia symptom risk high

Insomnia symptoms are often persistent, report researchers who found that targeting sleep-interfering behaviors may be one method of prevention.

13 Jan 2014

Merck announces FDA approval of ISENTRESS for oral suspension

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older.

9 Jan 2014

Support for DSM-5 mixed features specifier

Study findings uphold the value of the DSM-5 mixed features specifier of at least three depressive symptoms during a manic episode for diagnosing and classifying patients with mixed mania.

8 Jan 2014

Research: Daily meditation may improve symptoms of anxiety and depression

Some 30 minutes of meditation daily may improve symptoms of anxiety and depression, a new Johns Hopkins analysis of previously published research suggests.

7 Jan 2014

Sleep duration predicts chronic depression and anxiety

Short and long sleep duration, but not insomnia, predict a chronic course of depressive and anxiety disorders independent of symptom severity, research indicates.

6 Jan 2014

Japanese FIRST tool assesses vulnerability to insomnia

The Japanese version of the Ford Insomnia Response to Stress Test has been validated and confirmed as a reliable tool for assessing vulnerability to insomnia in healthy individuals.

24 Dec 2013

St. Louis College of Pharmacy's Amy Tiemeier suggests four easy resolutions for a healthier 2014

With the new year quickly approaching, many are beginning to think about resolutions. Amy Tiemeier, Pharm.D., BCPS, associate professor of pharmacy practice at St. Louis College of Pharmacy suggests four easy resolutions for a healthier 2014.

18 Dec 2013

Toddlers’ bedtime resistance may contribute to sleep problems

The bedtime you select for your toddler may be out of sync with his or her internal body clock, which can contribute to difficulties for youngsters attempting to settle in for the night, according to a new University of Colorado Boulder study.

17 Dec 2013

Insomnia impact on sleepiness and vigilance performance differs by age

Insomnia may affect people in different ways as they age, results of a prospective, 10-year study suggest.

16 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

13 Dec 2013

Researchers develop first test to identify acute mountain sickness

The first test to identify acute mountain sickness has been developed by a team of researchers in Italy and France and is presented today at EuroEcho-Imaging 2013. The test could revolutionise trekking and climbing by predicting who will develop the potentially deadly condition so they can avoid high altitudes, ascend more gradually or take preventative medication.

12 Dec 2013

Dietary amino acids improve sleep disturbances caused by brain injuries in animals

Scientists who fed a cocktail of key amino acids to mice improved sleep disturbances caused by brain injuries in the animals. These new findings suggest a potential dietary treatment for millions of people affected by traumatic brain injury (TBI)—a condition that is currently untreatable.

12 Dec 2013

Insomnia linked to increased GERD risk

Insomnia is associated with an increased risk for gastroesophageal reflux disease, findings from a cross-sectional study show.

9 Dec 2013

Insomnia symptoms linked to increased mortality

Certain aspects of insomnia are associated with an increased risk for mortality, shows an analysis of a large cohort of US men.

2 Dec 2013

San Diego School of Medicine receives grant to provide professional training to senior drivers

For the seventh consecutive year, the Training, Research and Education for Driving Safety (TREDS) program at the University of California, San Diego School of Medicine has been awarded a grant from the California Office of Traffic Safety (OTS) that will help keep our roadways and senior drivers safe through professional training.

27 Nov 2013